As the HER2 oncogene has immunosuppressive characteristics in the tumor microenvironment and stimulates cell proliferation and differentiation, it is not surprising that an increasing expression is accompanied with a negative prognostic effect (Kirchner et al. 2021; Press et al. 1990). The gene discussed is ERBB2; the disease is neoplasm.